2020-01-14 09:26:59 AIRI Air Industries
01/14/20 01/1409:26 01/14/2009:26 | Air Industries trading halted, news pending |
---|
Upgrade
|
Targa Resources upgraded to Buy from Hold at Stifel »
20:55 01/21/21 01/2120:55 01/21/2120:55
TRGP
Targa Resources
Stifel analyst Selman… Story temporarily locked. ShowHide Related Items >><<
|
Syndicate
|
Invitae 7.77M share Secondary priced at $51.50 »
20:42 01/21/21 01/2120:42 01/21/2120:42
NVTA
Invitae
The deal priced below the… Story temporarily locked. ShowHide Related Items >><<
|
Earnings
|
Notable companies reporting before tomorrow's open »
20:25 01/21/21 01/2120:25 01/21/2120:25
SLB
Schlumberger
Kansas City Southern
Regions Financial
Ally Financial
Huntington Bancshares
First Horizon
Notable companies… Notable companies reporting before tomorrow's open, with earnings consensus, include Schlumberger (SLB), consensus 17c... Kansas City Southern (KSU), consensus $1.92... Regions Financial (RF), consensus 42c... Ally Financial (ALLY), consensus $1.05... Huntington Bancshares (HBAN), consensus 29c... First Horizon (FHN), consensus 33c. ShowHide Related Items >><<
|
Syndicate
|
Passage Bio 7M share Secondary priced at $22.00 »
19:53 01/21/21 01/2119:53 01/21/2119:53
PASG
Passage Bio
The deal priced below the… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Aclaris gets orphan drug designation in cryopyrin-associated periodic syndrome »
19:50 01/21/21 01/2119:50 01/21/2119:50
ACRS
Aclaris Therapeutics
Aclaris announced that… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Novartis Gene Therapies gets FDA Orphan Drug Designation in Friedreich's Ataxia »
19:48 01/21/21 01/2119:48 01/21/2119:48
NVS
Novartis
Novartis Gene Therapies… Story temporarily locked. ShowHide Related Items >><<
|
Syndicate
|
BJ's Restaurants announces at-the-market equity program for $25M »
19:46 01/21/21 01/2119:46 01/21/2119:46
BJRI
BJ's Restaurants
The company currently… Story temporarily locked. ShowHide Related Items >><<
|
Earnings
|
BJ's Restaurants sees Q4 revenue $197.0M, consensus $210.97M »
19:45 01/21/21 01/2119:45 01/21/2119:45
BJRI
BJ's Restaurants
Sees Q4 SSS down 32.3%. … Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Amgen granted FDA Orphan Drug Designation for carfilzomib »
19:41 01/21/21 01/2119:41 01/21/2119:41
AMGN
Amgen
Amgen announced that the… Story temporarily locked. ShowHide Related Items >><<
|
Initiation
|
Autodesk initiated with a Sell at Goldman Sachs »
18:55 01/21/21 01/2118:55 01/21/2118:55
ADSK
Autodesk
Goldman Sachs analyst… Goldman Sachs analyst Kash Rangan initiated coverage of Autodesk with a Sell rating and $270 price target. The company is a "category leader" and looks poised to grow into a dominant design, automation software company in the cloud in key end markets including architecture, engineering, construction, and manufacturing, the analyst tells investors in a research note. Rangan is concerned however that the health of Autodesk's end markets remains uncertain, adding that the company's medium-term revenue and free cash flow targets are "increasingly back end loaded". ShowHide Related Items >><<
|
Initiation
|
Oracle initiated with a Sell at Goldman Sachs »
18:53 01/21/21 01/2118:53 01/21/2118:53
ORCL
Oracle
Goldman Sachs analyst… Story temporarily locked. ShowHide Related Items >><<
|
Initiation
|
VMware initiated with a Neutral at Goldman Sachs »
18:52 01/21/21 01/2118:52 01/21/2118:52
VMW
VMware
Goldman Sachs analyst… Goldman Sachs analyst Kash Rangan initiated coverage of VMware with a Neutral rating and $150 price target. The analyst is confident the company can hit a $20B revenue target, though there are "several" near-term headwinds. Rangan added that VMware is the "most successful" infrastructure software company to have attained scale and profitability. ShowHide Related Items >><<
|
Initiation
|
Snowflake initiated with a Neutral at Goldman Sachs »
18:51 01/21/21 01/2118:51 01/21/2118:51
SNOW
Snowflake
Goldman Sachs analyst… Story temporarily locked. ShowHide Related Items >><<
|
Initiation
|
Elastic initiated with a Neutral at Goldman Sachs »
18:50 01/21/21 01/2118:50 01/21/2118:50
ESTC
Elastic
Goldman Sachs analyst… Goldman Sachs analyst Kash Rangan initiated coverage of Elastic with a Neutral rating and $190 price target. The analyst said his price target is based on the firm's fundamental valuation framework, adding that his thesis is that Elastic's combination of technology and differentiated customer approach has the potential to disrupt the "fragmented" IT Operations market. ShowHide Related Items >><<
|
Initiation
|
Intuit assumed with a Neutral at Goldman Sachs »
18:49 01/21/21 01/2118:49 01/21/2118:49
INTU
Intuit
Goldman Sachs analyst… Story temporarily locked. ShowHide Related Items >><<
|
Initiation
|
ServiceNow assumed with a Buy at Goldman Sachs »
18:47 01/21/21 01/2118:47 01/21/2118:47
NOW
ServiceNow
Goldman Sachs analyst… Goldman Sachs analyst Kash Rangan assumed coverage of ServiceNow with a Buy rating and $670 price target. The company stands "well positioned" to become an over $15B revenue cloud applications software firm by 2026, the analyst tells investors in a research note. Rangan adds that ServiceNow's operating margins could then hit 30%-35% and free cash flow margins could potentially reach 35%-40% thanks to its "very efficient" customer acquisition economics and expansion beyond its core ITSM market into adjacent markets. ShowHide Related Items >><<
|
Initiation
|
Splunk assumed with a Buy at Goldman Sachs »
18:46 01/21/21 01/2118:46 01/21/2118:46
SPLK
Splunk
Goldman Sachs analyst… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Blue Ridge Bankshares and Bay Banks of Virginia shareholders approve merger »
18:45 01/21/21 01/2118:45 01/21/2118:45
BRBS
Blue Ridge Bankshares
Blue Ridge Bankshares and… Blue Ridge Bankshares and Bay Banks of Virginia shareholders approved the previously announced merger of Bay Banks into Blue Ridge. The combined company would have approximately $2.8B in assets, $1.9B in deposits, and $2.1B in loans. ShowHide Related Items >><<
|
Initiation
|
Adobe initiated with a Buy at Goldman Sachs »
18:44 01/21/21 01/2118:44 01/21/2118:44
ADBE
Adobe
Goldman Sachs analyst… Story temporarily locked. ShowHide Related Items >><<
|
Initiation
|
Workday initiated with a Buy at Goldman Sachs »
18:44 01/21/21 01/2118:44 01/21/2118:44
WDAY
Workday
Goldman Sachs analyst… Goldman Sachs analyst Kash Rangan initiated coverage of Workday with a Buy rating and $300 price target. The company is a "uniquely positioned application software company addressing massive cloud replacement cycles in an over $90B total addressable market" and spans human capital resources, financials, analytics, planning, and procurement, the analyst tells investors in a research note. Workday is poised to grow into an over $10B business catalyzed by financials moving to the cloud following its core HCM marquee product, Rangan adds. ShowHide Related Items >><<
|
Initiation
|
Salesforce initiated with a Buy at Goldman Sachs »
18:42 01/21/21 01/2118:42 01/21/2118:42
CRM
Salesforce
Goldman Sachs analyst… Story temporarily locked. ShowHide Related Items >><<
|
Initiation
|
Microsoft initiated with a Buy at Goldman Sachs »
18:39 01/21/21 01/2118:39 01/21/2118:39
MSFT
Microsoft
Goldman Sachs analyst… Goldman Sachs analyst Kash Rangan initiated coverage of Microsoft with a Buy rating and $285 price target. The company stands out "uniquely" with its presence across all layers of the cloud stack, the analyst tells investors in a research note. Rangan adds that Microsoft is well positioned to double its $60B commercial cloud business which includes Azure, Office 365, Dynamics, and LinkedIn Commercial into a $120B-$140B business longer term. The analyst further states that Office 365 could potentially double its installed base from over 255M to 500M given the massive number of knowledge workers worldwide. ShowHide Related Items >><<
|
On The Fly
|
Fly Intel: After-Hours Movers »
18:35 01/21/21 01/2118:35 01/21/2118:35
SIVB
SVB Financial
Western Alliance
Independent Bank
Bank OZK
Fluidigm
MediciNova
Sierra Wireless
Aldeyra
Amarin
IBM
Seagate
PPG
Intuitive Surgical
CSX
Precigen
Aurora Cannabis
Ford
Check out this evening's… ShowHide Related Items >><<
|
Hot Stocks
|
Amarin announces CSC included icosapent ethyl in CD prevention guidelines »
18:27 01/21/21 01/2118:27 01/21/2118:27
AMRN
Amarin
The company states:… The company states: "Amarin announced that the Chinese Society of Cardiology, or CSC, has included icosapent ethyl in its updated Guidelines for Primary Prevention of Cardiovascular Diseases for 2021 as published in the Chinese Journal of Cardiovascular Diseases. The guideline authors include "icosapent ethyl grams twice a day as a treatment consideration to further lower atherosclerotic cardiovascular disease (ASCVD) in the appropriate patient population. In November 2020, Amarin shared positive, statistically significant top-line results from a Phase 3 clinical trial of VASCEPA conducted in China by Amarin's partner, Edding. The study, which investigated VASCEPA as a treatment for patients with very high triglycerides (greater than or equal to500 mg/dL), met its primary efficacy endpoint and demonstrated a safety profile similar to placebo. This pivotal study mirrored Amarin's MARINE study in patients from the United States and other countries and showed consistency across the Chinese and non-Chinese study populations. These findings will provide support as Edding progresses towards and through the next steps of regulatory submission and review of VASCEPA for potential approval in Mainland China. The CSC recommendation is classified as a Category IIa recommendation denoting that icosapent ethyl is useful and effective and should be considered for treatment of at-risk patients. The classification is an Evidence Level B recommendation which reflects that the evidence comes from a single randomized trial or multiple large non-randomized studies. CSC cited that its recommendations are supported by the results of the REDUCE-IT cardiovascular outcomes study. The CSC does not provide endorsements of any brand name commercial product. Accordingly, CSC Guidelines for Primary Prevention of Cardiovascular Diseases reference icosapent ethyl. The CSC guideline does not reference VASCEPA, the brand name of icosapent ethyl in the United States, and such guideline should not be construed as an endorsement or approval by the CSC of VASCEPA." ShowHide Related Items >><<
|
Hot Stocks
|
Aldeyra rises 6% after 1.37M share purchase disclosed by Perceptive Advisors »
18:25 01/21/21 01/2118:25 01/21/2118:25
ALDX
Aldeyra
In a regulatory filing,… Story temporarily locked. ShowHide Related Items >><<
|